11/21
04:30 pm
bioa
BioAge Labs to Present at Upcoming Investor Conferences
Neutral
Report
BioAge Labs to Present at Upcoming Investor Conferences
11/14
12:01 pm
bioa
CHMP issues positive recommendation for approval of lecanemab in the EU
Low
Report
CHMP issues positive recommendation for approval of lecanemab in the EU
11/14
12:00 pm
bioa
CHMP issues positive recommendation for approval of lecanemab in the EU
Low
Report
CHMP issues positive recommendation for approval of lecanemab in the EU
11/13
02:07 am
bioa
BioAge Labs Reports Strong Q3 2024 Achievements [Yahoo! Finance]
Medium
Report
BioAge Labs Reports Strong Q3 2024 Achievements [Yahoo! Finance]
11/7
11:21 pm
bioa
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
Medium
Report
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
11/7
11:19 pm
bioa
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
Medium
Report
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
11/7
04:30 pm
bioa
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/6
02:50 am
bioa
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
Medium
Report
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
11/6
02:47 am
bioa
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
Medium
Report
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
11/4
09:00 am
bioa
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
Low
Report
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
10/31
07:45 pm
bioa
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
High
Report
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
10/31
07:43 pm
bioa
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
High
Report
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
10/31
03:44 am
bioa
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Medium
Report
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
10/31
03:42 am
bioa
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Medium
Report
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
10/30
07:07 am
bioa
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Low
Report
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
10/30
07:04 am
bioa
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Low
Report
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
10/30
04:10 am
bioa
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Low
Report
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
10/30
04:06 am
bioa
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Low
Report
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
10/24
09:00 am
bioa
BioAge Labs to Present at Jefferies London Healthcare Conference
Medium
Report
BioAge Labs to Present at Jefferies London Healthcare Conference
10/16
10:50 pm
bioa
Eisai will request reconsideration of initial decision for lecanemab in Australia
Medium
Report
Eisai will request reconsideration of initial decision for lecanemab in Australia
10/16
10:45 pm
bioa
Eisai will request reconsideration of initial decision for lecanemab in Australia
Medium
Report
Eisai will request reconsideration of initial decision for lecanemab in Australia
10/1
04:30 pm
bioa
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
Low
Report
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
9/26
10:29 am
bioa
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq [Yahoo! Finance]
High
Report
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq [Yahoo! Finance]
9/25
08:00 pm
bioa
BioAge Labs Announces Pricing of Upsized Initial Public Offering
High
Report
BioAge Labs Announces Pricing of Upsized Initial Public Offering